CoChat

Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo

Open access
Wendel, Hans-Guido, Malina, Abba, Zhao, Zhen, Zender, Lars, Kogan, Scott C., Cordon-Cardo, Carlos, Pelletier, Jerry, Lowe, Scott W. · 2006 · Cancer Research
Cited by 97

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The phosphatidylinositol-3-OH kinase [PI(3)K] pathway is frequently activated in human cancers and represents a rational target for therapeutic intervention. We have previously shown that enforced expression of Akt, which is a downstream effector of PI(3)K, could promote tumorigenesis and drug resistance in the Eμ-myc mouse lymphoma model, and that these tumors were particularly sensitive to inhibition of mammalian target of rapamycin (mTOR) with rapamycin when combined with conventional chemotherapy. We now show that reduced dosage of PTEN, a negative regulator of PI(3)K signaling, is sufficient to activate Akt, but has only a modest effect on lymphomagenesis in the same model. Nonetheless, loss of even one PTEN allele resulted in lymphomas that were resistant to conventional chemotherapy yet sensitive to rapamycin/chemotherapy combinations. These effects could be recapitulated by using RNA interference to suppress PTEN expression in lymphomas, which were previously established in the absence of PI(3)K lesions. Finally, the introduction of lesions that act downstream of mTOR (eIF4E) or disable apoptosis (Bcl-2 and loss of p53) into PTEN+/− lymphomas promoted resistance to rapamycin/chemotherapy combinations. Thus, whether activation of the PI(3)K pathway confers sensitivity or resistance to therapy depends on the therapy used as well as secondary genetic events. Understanding these genotype-response relationships in human tumors will be important for the effective use of rapamycin or other compounds targeting the PI(3)K pathway in the clinic. (Cancer Res 2006; 66(15): 7639-46)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-0419

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 97

Metadata

Authors
Wendel, H.-G., Malina, A., Zhao, Z., Zender, L., Kogan, S. C., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W.
Venue
Cancer Research
Published
2006-08-01
Volume
66
Issue
15
Pages
7639-7646
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2114787204
Cited by
97
References
7
FWCI
5.16
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-0419
The paper
Wendel, H.-G., Malina, A., Zhao, Z., Zender, L., Kogan, S. C., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2006). Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-0419

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.